Page last updated: 2024-09-05

organophosphonates and osteoprotegerin

organophosphonates has been researched along with osteoprotegerin in 2 studies

Compound Research Comparison

Studies (organophosphonates)	Trials (organophosphonates)	Recent Studies (post-2010) (organophosphonates)	Studies (osteoprotegerin)	Trials (osteoprotegerin)	Recent Studies (post-2010) (osteoprotegerin)
9,968	880	3,596	5,108	212	2,726

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bijlsma, JW; Lems, WF	1
Brown, TT; Labbato, D; McComsey, GA; Ross, AC; Storer, N	1

Other Studies

2 other study(ies) available for organophosphonates and osteoprotegerin

Article	Year
[Clinical implications of new insights into the regulation of bone resorption]. Nederlands tijdschrift voor geneeskunde, 2005, Jul-23, Volume: 149, Issue:30 Topics: Bone Diseases; Bone Resorption; Carrier Proteins; Glycoproteins; Humans; Membrane Glycoproteins; Organophosphonates; Osteoblasts; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor	2005
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antiviral therapy, 2011, Volume: 16, Issue:7 Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Remodeling; CD4 Lymphocyte Count; Collagen Type I; Cytokines; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; NF-kappa B; Organophosphonates; Osteoprotegerin; Protease Inhibitors; RANK Ligand; Tenofovir; Tumor Necrosis Factor-alpha; Young Adult	2011

Article

Year

[Clinical implications of new insights into the regulation of bone resorption].

Nederlands tijdschrift voor geneeskunde, 2005, Jul-23, Volume: 149, Issue:30

Topics: Bone Diseases; Bone Resorption; Carrier Proteins; Glycoproteins; Humans; Membrane Glycoproteins; Organophosphonates; Osteoblasts; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor

2005

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Antiviral therapy, 2011, Volume: 16, Issue:7

Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Remodeling; CD4 Lymphocyte Count; Collagen Type I; Cytokines; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; NF-kappa B; Organophosphonates; Osteoprotegerin; Protease Inhibitors; RANK Ligand; Tenofovir; Tumor Necrosis Factor-alpha; Young Adult

2011